**Artiva Biotherapeutics Reports Financial Results and Operational Progress in Latest 10-K Filing**
Artiva Biotherapeutics, a clinical-stage biotechnology company, reported its financial results and provided an update on its operational progress in its recent 10-K filing. The company, focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers, reported a net loss of $83.9 million for the year ended December 31, 2025, compared to a net loss of $65.4 million for the previous year. This increase in net loss is primarily attributed to higher research and development expenses as the company advances its lead product candidate, AlloNK, through clinical trials. As of December 31, 2025, Artiva held $108.0 million in cash, cash equivalents, and investments.
The company's research and development expenses for 2025 totaled $69.5 million, up from $50.3 million in 2024. This increase reflects the ongoing clinical trials of AlloNK and other product development activities. General and administrative expenses also rose to $20.3 million in 2025 from $17.2 million in 2024, driven by increased personnel costs and operational expenses associated with being a public company. Artiva generated no license and development support revenue in 2025, compared to $0.3 million in 2024, which was related to GC Cell's development support activities under the AB-201 Agreement.
Operationally, Artiva highlighted the progress of AlloNK, its lead product candidate, which is currently being evaluated in clinical trials for B-cell driven autoimmune diseases. The company is prioritizing refractory rheumatoid arthritis (RA) as its lead indication and expects to share initial clinical response data from RA patients in the first half of 2026. Artiva also plans to conduct regulatory interactions with the FDA to align on the pivotal trial design for AlloNK in refractory RA. The company emphasized its manufacturing-first approach, leveraging its purpose-built cell production center in San Diego, California, and its strategic partnership with GC Cell.
Looking ahead, Artiva Biotherapeutics anticipates that its existing cash resources will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2027. The company plans to continue advancing AlloNK through clinical development and exploring its potential in additional autoimmune indications. Artiva also intends to evaluate partnerships to further its NK cell development and manufacturing efforts, with the goal of delivering its product candidates to patients in need.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics develops off-the-shelf natural killer (NK) cell therapies targeting autoimmune diseases and cancers. Its lead candidate, AlloNK, enhances antibody-dependent cellular cytotoxicity (ADCC) in combination with B-cell targeted monoclonal antibodies, aiming to deplete pathogenic B-cells. The company focuses on scalable manufacturing, outpatient administration, and broad indications, leveraging proprietary processes and strategic collaborations to deliver accessible, safe, and effective cell therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.